JUBILANT LIFESCIENCES

May 25, 2016

BSE Limited
Corporate Service Department
1st Floor, New Trading Ring
Rotunda Building, P.J. Tower
Dalal Street, Fort
Mumbai - 400 001

The National Stock Exchange of India Ltd.
Exchange Plaza,
Bandra Kurla Complex
Bandra (E)
Mumbai – 400 051

Dear Sirs,

We enclose a copy of the Announcement being issued by the Company.

This is for your kind information and records.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

Encl.: as above

Jubilant Life Sciences Limited
1-A, Sector 16-A,
Noida-201 301, UP, India
Tel:+91 120 4361000
Fax:+91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624

Jubilant Life Sciences Ltd.
1A, Sector 16A, Noida – 201301, India
Tel.: +91 120 4361000
www.jubl.com

Jubilant Life Sciences receives ANDA approval for 0.9% Sodium Chloride Injection USP

Noida (UP), India, Wednesday, May 25, 2016

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has announced that its subsidiary Jubilant HollisterStier LLC, Spokane, Washington, has received Abbreviated New Drug Application (ANDA) approval for **0.9% Sodium Chloride Injection USP, 3 mL and 10 mL vials,** the generic equivalent of Sodium Chloride 0.9% in Plastic Container, of Hospira, Inc., which is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

This is the first ANDA approval in injectables received by the company. We have filed two injectables and one ophthalmic product as on March 31, 2016.

About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides Services in Contract Manufacturing of Sterile Products and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 12 world-class manufacturing facilities in India, US and Canada and a team of about 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: www.jubl.com.

For more information please contact:

For Investors

Ravi Agrawal / Anupam Jain
Jubilant Life Sciences Limited
Ph: +91-120 436 1002 / 1021
E-mail: ravi_agrawal@jubl.com
anupam_jain@jubl.com

Siddharth Rangnekar / Karl Kolah
Citigate Dewe Rogerson
Tel: +91 22 6645 1209 / 1220
E-mail: siddharth@cdr-india.com
karl@cdr-india.com

For Media

Sudhakar Safaya / Neha Garg
Jubilant Life Sciences Limited
Ph: +91-120 436 1062 / 1067
E-mail: sudhakar_safaya@jubl.com
neha_garg@jubl.com

Kanika Mittal
Perfect Relations
Ph: +91 9899574833
E-mail: kmitttal@perfectrelations.com

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.